{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"}],"units":"Participants"}],"description":"Overall response includes the rate of complete response (CR), partial response (PR), minimal response (MR), stabl disease (SD) and progressive disease (PD). Minor response is \\>25%-50% reduction in serum IgM from baseline. Partial Response is (\\>50-90% reduction in serum IgM from baseline. Very Good Partial Response is \\>90% reduction in serum IgM from baseline. Complete Response is resolution of all symptoms, normalization of serum IgM with disappearance of IgM paraprotein, resolution of any adenopathy or splenomegaly.","groups":[{"description":"\\- IDR The study treatment will consist on an induction and a maintenance phase. Dose modification will be permitted for toxicity\n\n* Induction cycles will be 4 weeks long, Maintenance cycles 8 weeks long.\n* Ixazomib- administered orally on predetermined days and dosage during Induction and Maintenance Phase\n* Dexamethasone- administered via IV or orally on predetermined days and dosage during Induction and Maintenance Phase\n* Rituximab- administered via IV on predetermined days and dosage during Induction and Maintenance Phase\n\nIxazomib: Doses given on Days 1, 8, and 15 in induction and maintenance cycles.\n\nDexamethasone: Doses given on Days 1, 8, and 15 in induction and maintenance cycles.\n\nRituximab: Doses given on Day 1 of induction and maintenance cycles.","id":"OG000","title":"Ixazomib, Dexamethasone, Rituximab"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All participants who received at least 1 cycle of therapy.","reportingStatus":"POSTED","timeFrame":"2 Years","title":"Overall Response Rate","type":"SECONDARY","unitOfMeasure":"Participants"}